Wen Kenneth相关文献与解析，生知库 | 链接生命科学的每一步

Dutta, Debasmita; Liu, Jiye; Wen, Kenneth; Ray, Arghya; Salatino, Alessandro; Liu, Xiangdong; Gulla, Annamaria; Hideshima, Teru; Song, Yan; Anderson, Kenneth C

多发性骨髓瘤

骨髓瘤

发表日期：2025

文献求助收藏

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

GABARAP 的缺失介导多发性骨髓瘤对免疫原性化疗的耐药性

期刊:Blood

影响因子:23.1

doi:10.1182/blood.2023022777

Gulla, Annamaria; Morelli, Eugenio; Johnstone, Megan; Turi, Marcello; Samur, Mehmet K; Botta, Cirino; Cifric, Selma; Folino, Pietro; Vinaixa, Delaney; Barello, Francesca; Clericuzio, Cole; Favasuli, Vanessa Katia; Maisano, Domenico; Talluri, Srikanth; Prabhala, Rao; Bianchi, Giada; Fulciniti, Mariateresa; Wen, Kenneth; Kurata, Keiji; Liu, Jiye; Penailillo, Johany; Bragoni, Alberto; Sapino, Anna; Richardson, Paul G; Chauhan, Dharminder; Carrasco, Ruben D; Hideshima, Teru; Munshi, Nikhil C; Anderson, Kenneth C

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

更正：BRD9降解破坏多发性骨髓瘤中的核糖体生物合成

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-24-2112

Kurata, Keiji; Samur, Mehmet K; Liow, Priscilla; Wen, Kenneth; Yamamoto, Leona; Liu, Jiye; Morelli, Eugenio; Gulla, Annamaria; Tai, Yu-Tzu; Qi, Jun; Hideshima, Teru; Anderson, Kenneth C

BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma

BCMA靶向硼替佐米纳米疗法可提高多发性骨髓瘤的治疗效果，克服耐药性，并调节免疫微环境。

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-023-00955-y

Dutta, Debasmita; Liu, Jiye; Wen, Kenneth; Kurata, Keiji; Fulciniti, Mariateresa; Gulla, Annamaria; Hideshima, Teru; Anderson, Kenneth C

Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1

开发一种对 c-Jun N 端蛋白激酶 (JNK) 2/3 具有选择性而非 JNK1 的共价抑制剂

期刊:Journal of Medicinal Chemistry

影响因子:6.8

doi:10.1021/acs.jmedchem.2c01834

Wenchao Lu ,Yao Liu ,Yang Gao ,Qixiang Geng ,Deepak Gurbani ,Lianbo Li ,Scott B Ficarro ,Cynthia J Meyer ,Dhiraj Sinha ,Inchul You ,Jason Tse ,Zhixiang He ,Wenzhi Ji ,Jianwei Che ,Audrey Y Kim ,Tengteng Yu ,Kenneth Wen ,Kenneth C Anderson ,Jarrod A Marto ,Kenneth D Westover ,Tinghu Zhang ,Nathanael S Gray

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.

靶向 LAG3/GAL-3 以克服免疫抑制并增强多发性骨髓瘤的抗肿瘤免疫反应

期刊:Leukemia

影响因子:13.4

doi:10.1038/s41375-021-01301-6

Bae Jooeun, Accardi Fabrizio, Hideshima Teru, Tai Yu-Tzu, Prabhala Rao, Shambley Aaron, Wen Kenneth, Rowell Sean, Richardson Paul G, Munshi Nikhil C, Anderson Kenneth C

Î³-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.

γ-分泌酶抑制剂可增强靶向BCMA的双特异性抗体对多发性骨髓瘤细胞的疗效，而不会损害T细胞的活化和分化

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-022-00716-3

Chen Hailin, Yu Tengteng, Lin Liang, Xing Lijie, Cho Shih-Feng, Wen Kenneth, Aardalen Kimberly, Oka Adwait, Lam Joni, Daley Mike, Lu Haihui, Munshi Nikhil, Anderson Kenneth C, Tai Yu-Tzu

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

CD8+抗BCMA mRNA CAR T细胞治疗多发性骨髓瘤的临床前评估

期刊:Leukemia

影响因子:13.4

doi:10.1038/s41375-020-0951-5

Lin Liang, Cho Shih-Feng, Xing Lijie, Wen Kenneth, Li Yuyin, Yu Tengteng, Hsieh Phillip A, Chen Hailin, Kurtoglu Metin, Zhang Yi, Andrew Stewart C, Munshi Nikhil, Anderson Kenneth C, Tai Yu-Tzu

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

VIS832是一种新型的靶向CD138的单克隆抗体，能够有效杀伤人多发性骨髓瘤细胞，并且在体外和体内均能与免疫调节剂（IMiDs）或硼替佐米产生协同作用。

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-020-00378-z

Yu, Tengteng; Chaganty, Bharat; Lin, Liang; Xing, Lijie; Ramakrishnan, Boopathy; Wen, Kenneth; Hsieh, Phillip A; Wollacott, Andrew; Viswanathan, Karthik; Adari, Hedy; Cho, Shih-Feng; Li, Yuyin; Chen, Hailin; Yang, Wenjuan; Xu, Yan; An, Gang; Qiu, Lugui; Munshi, Nikhil; Babcock, Gregory; Shriver, Zachary; Myette, James R; Anderson, Kenneth C; Tai, Yu-Tzu

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

BCMA-mRNA疫苗是治疗多发性骨髓瘤的一种很有前景的疗法。

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

GABARAP 的缺失介导多发性骨髓瘤对免疫原性化疗的耐药性

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

更正：BRD9降解破坏多发性骨髓瘤中的核糖体生物合成

BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma

BCMA靶向硼替佐米纳米疗法可提高多发性骨髓瘤的治疗效果，克服耐药性，并调节免疫微环境。

Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1

开发一种对 c-Jun N 端蛋白激酶 (JNK) 2/3 具有选择性而非 JNK1 的共价抑制剂

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.

靶向 LAG3/GAL-3 以克服免疫抑制并增强多发性骨髓瘤的抗肿瘤免疫反应

Î³-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.

γ-分泌酶抑制剂可增强靶向BCMA的双特异性抗体对多发性骨髓瘤细胞的疗效，而不会损害T细胞的活化和分化

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

CD8+抗BCMA mRNA CAR T细胞治疗多发性骨髓瘤的临床前评估

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

VIS832是一种新型的靶向CD138的单克隆抗体，能够有效杀伤人多发性骨髓瘤细胞，并且在体外和体内均能与免疫调节剂（IMiDs）或硼替佐米产生协同作用。